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351 
RESEARCH ETHICS COMMITTEES 
(RECS)/INSTITUTIONAL REVIEW BOARDS 
(IRBS) AND THE GLOBALIZATION OF CLINICAL 
RESEARCH: CAN ETHICAL OVERSIGHT OF 
HUMAN SUBJECTS RESEARCH BE 
STANDARDIZED? 
INTRODUCTION  
Current United States’ policy requires federally funded research studies 
involving human subjects to be approved by an interdisciplinary 
committee called an institutional review board (IRB).
1
 IRBs exist to 
protect the safety and welfare of human subjects participating in research 
studies. Although oversight of human subjects research and, consequently, 
IRBs, is governed by federal regulations, the operation of IRBs remain 
largely mysterious to those other than IRB members themselves. This 
Note reviews the establishment of both United States regulations and 
international guidelines governing human subjects research, the changing 
environment of biomedical research, and potential reforms for improving 
the efficiency and efficacy of ethical review performed by IRBs.  
Part I of this Note reviews the establishment of the federal regulations 
governing human subjects research that originates in the United States as 
well as the ethical principles that guided their creation. Part II presents 
current policies governing the structure and function of IRBs and also 
describes potential policy revisions relevant to the function of IRBs. Part 
III examines current controversies regarding research oversight systems. 
Finally, Part IV offers recommendations for improving human research 
subject oversight.  
 
 
 1. Committees that review the ethics of human subjects research are called IRBs in the United 
States. Different names are used for such committees in other countries, including research ethics 
committees or ethics review committees. Sandra L. Alfano, Conducting Research with Human 
Subjects in International Settings: Ethical Considerations, 86 YALE J. BIO. & MED. 315, 317 (2013). 
In this Note, references to committees that oversee human subjects in the United States will be 
identified as IRBs. References to such committees in nations outside the United States will be 
identified as Research Ethics Committees (RECs).  
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I. BACKGROUND 
A. Regulating Human Subjects Research 
The establishment of ethical standards for research involving human 
subjects on an international scale almost certainly began with the 
Nuremburg Code in 1947.
2
 Subsequently, in 1964, the World Medical 
Association (WMA) adopted a statement of ethical principles for 
conducting medical research with humans, known as The Declaration of 
Helsinki.
3
 Similarly, the Council for International Organizations of 
Medical Sciences (CIOMS)
4
 has published ethical guidelines for research 
involving human subjects that emphasize ethical review and informed 
consent.
5
 
Before the 1960s, the ethics of research involving human subjects in 
the United States was a matter for individual research investigators to 
address. By the mid-1960s, however, the National Institutes of Health 
 
 
 2. Ruth Macklin, Appropriate Ethical Standards, in THE OXFORD TEXTBOOK OF CLINICAL 
RESEARCH ETHICS 711, 711 (Ezekiel J. Emanuel et al. eds., 2008). The Nuremberg Code, delivered in 
August 1947 as the final judgment in the Doctors Trial at Nuremberg, Germany, consists of ten rules 
directed at protecting human research subjects. George J. Annas & Michael A. Grodin, The 
Nuremberg Code, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 136, 138 (Ezekiel J. 
Emanuel et al. eds., 2008). During the trial, United States judges heard evidence of murder and torture 
supervised by Nazi physicians in the name of medical research. Id. at 136. A central strength of the 
Code is its reliance on the principle of informed consent “insisting that the voluntary, competent, 
informed, and understanding consent of the research subject is a necessary (but not sufficient) 
prerequisite for lawful human experimentation . . . .” Id. at 138. 
 3. The WMA was founded in Paris in 1947 as an association for national medical associations. 
History, WORLD MEDICAL ASSOCIATION, Nov. 8, 2015, http://www.wma.net/en/60about/70history/ 
index.html. At the time it was established, members were particularly concerned with the violations of 
human rights and ethics that had taken place in Germany and elsewhere during World War II. Id. The 
Declaration of Helsinki was adopted by the WMA at its annual General Assembly in Helsinki in 1964. 
Richard E. Ashcroft, The Declaration of Helsinki, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH 
ETHICS 141, 141–43 (Ezekiel J. Emanuel et al. eds., 2008). The Declaration of Helsinki asserts: 
“Medical research is subject to ethical standards that promote and ensure respect for all human 
subjects and protect their health and rights.” WMA Declaration of Helsinki—Ethical Principles for 
Medical Research Involving Human Subjects, WORLD MEDICAL ASSOCIATION, http://www.wma.net/ 
en/30publications/10policies/b3/index.html (last visited Oct. 23, 2015). The Declaration emphasizes 
that some research populations include individuals who cannot give or refuse consent and those who 
may be unduly influenced. Such groups should thus “receive specifically considered protection.” Id. 
 4. CIOMS is a collaborative entity of two United Nations agencies—the World Health 
Organization (WHO) and the United Nations Educational, Scientific, and Cultural Organization 
(UNESCO). Juhana E. Idänpään-Heikkilä & Sev S. Fluss, International Ethical Guidance From the 
Council for International Organizations of Medical Sciences, in THE OXFORD TEXTBOOK OF CLINICAL 
RESEARCH ETHICS 168, 168 (Ezekiel J. Emanuel et al. eds., 2008). 
 5. See CIOMS International Ethical Guidelines for Biomedical Research Involving Human 
Subjects, COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES, http://www.cioms. 
ch/images/stories/CIOMS/guidelines/guidelines_nov_2002_blurb.htm (last visited Oct. 23, 2015). 
https://openscholarship.wustl.edu/law_globalstudies/vol15/iss2/8
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(NIH), an agency of the Department of Health and Human Services 
(DHHS),
6
 was devoting more resources to clinical research activities and 
establishing itself as the primary funding vehicle for biomedical research.
7
 
As government funding for biomedical research increased, officials 
became concerned about the potential conflict of protecting subjects from 
harm while encouraging researchers to pursue studies to develop new 
knowledge.
8
 In addition, the public remained disturbed about the horrific 
abuses suffered by prisoners in the name of experimentation during World 
War II.
9
 Responding to this climate, the NIH Director proposed in 1965 
that the agency establish a requirement for investigators to submit research 
protocols for peer evaluation of risks the proposed studies presented to 
human subjects.
10
 In 1966, agency authorities agreed to a new rule 
requiring that institutions receiving federal funding for research involving 
human subjects establish committees to consider the ethics of proposed 
research studies involving human subjects.
11
 The committee would “assure 
an independent determination: (1) of the rights and welfare of the 
individual or individuals involved, (2) of the appropriateness of the 
methods used to determine informed consent, and (3) of the risks and 
potential medical benefits of the investigation.”12 Adoption of the new rule 
thus produced the first IRBs.  
In 1972, the need for additional regulatory action addressing ethics 
review was reinforced by revelations of a United States research scandal: 
The nation learned about the Tuskegee Syphilis Study–a government-
sponsored study in which nearly four hundred African American men had 
been deprived of treatment for syphilis for more than thirty years.
13
 The 
study, started in the 1930s, continued long after the discovery of penicillin 
and after the review and approval by an IRB at the Tuskegee Institute.
14
 In 
1974, Congress responded by passing legislation creating the National 
 
 
 6. Until 1980, DHHS was the Department of Health, Education, and Welfare (DHEW). 
Historical Highlights, U.S. DEP’T OF HEALTH & HUMAN SERVICES, Nov. 8, 2015, http://www.hhs. 
gov/about/historical-highlights/index.html.  
 7. Charles R. McCarthy, The Origins and Policies That Govern Institutional Review Boards, in 
THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 541, 543 (Ezekiel J. Emanuel et al. eds., 
2008). 
 8. Id. 
 9. Introduction, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 3, 3–4 (Ezekiel J. 
Emanuel et al. eds., 2008). 
 10. McCarthy, supra note 7, at 542. 
 11. Id. at 546. 
 12. Id. 
 13. James H. Jones, The Tuskegee Syphilis Experiment, in THE OXFORD TEXTBOOK OF CLINICAL 
RESEARCH ETHICS 86, 86 (Ezekiel J. Emanuel et al. eds., 2008).  
 14. McCarthy, supra note 7, at 547. 
Washington University Open Scholarship
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Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (“National Commission”).15 Four years later, the 
National Commission issued a report outlining recommendations for 
regulations governing IRBs based in part on review of how IRBs 
performed during their first decade. The National Commission presented 
its belief that human subjects should be protected by local review 
committees governed by uniform federal regulations. The National 
Commission further recognized the importance of placing review at the 
local level with individuals who could best understand the research 
environment.
16
 At the same time, however, incidents such as The 
Tuskegee Syphilis Study made it clear that uniform, national oversight for 
IRBs was necessary.
17
 
The National Commission recommended that a single federal office be 
established to provide accreditation and compliance assessment of IRBs as 
well as ethical education activities for IRB members.
18
 In addition, the 
Commission recommended that IRBs: be made up of individuals from 
“diverse backgrounds,” include one member not affiliated with the 
institution, maintain sufficient records, and have the authority to approve, 
require modifications of, and disapprove all research proposals involving 
human subjects at the institution.
19
 The Commission further recommended 
that federal regulations be adopted that would require IRBs: to assess the 
risks and benefits of research to potential human subjects, ensure that the 
process of selecting human subjects was equitable, and ensure informed 
consent was obtained and appropriately documented for all research 
studies.
20
 
In 1978, the National Commission published a document commonly 
referred to as The Belmont Report,
21
 which identified three moral 
 
 
 15. See id. at 548 (referring to National Research Act, Pub. L. No. 93-348, 88 Stat. 342 (1974)). 
 16. U.S. DEPT. OF HEALTH, EDUC. & WELFARE, DHEW Pub. No. (OS) 78-0008, NAT’L COMM’N 
FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL RESEARCH, REPORT AND 
RECOMMENDATIONS INSTITUTIONAL REVIEW BOARDS 1 (1978). 
 17. The Commission emphasized the critical need for independent ethical review in general: 
[I]nvestigators should not have sole responsibility for determining whether research involving 
human subjects fulfills ethical standards. Others, who are independent of the research, must 
share the responsibility, because investigators are always in positions of potential conflict by 
virtue of their concern with the pursuit of knowledge as well as the welfare of the human 
subjects of their research. Id. 
 18. Id. at 10. 
 19. Id. at 13. 
 20. Id. at 19–21. 
 21. The Belmont Report is a document outlining important moral principles that was written and 
published by the National Commission for the Protection of Human Subjects of Biomedical Research 
in 1978. Tom L. Beauchamp, The Belmont Report, in THE OXFORD TEXTBOOK OF CLINICAL 
https://openscholarship.wustl.edu/law_globalstudies/vol15/iss2/8
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principles that should guide the conduct of ethical research: respect for 
persons, beneficence, and justice.
22
 The Belmont principles provided a 
guide for IRBs and a framework for drafting federal regulations.
23
 In 1981, 
the Department of Health and Human Services (DHHS)–then the 
Department of Health, Education and Welfare–adopted regulations 
designed to protect human subjects that incorporated many of the 
recommendations of the National Commission.
24
 Ten years later, fourteen 
other federal departments and agencies joined DHHS in adopting a 
uniform set of rules for the protection of human subjects. These rules 
closely resembled the earlier regulations and later became known as the 
Common Rule.
25
  
The regulations of the Common Rule require that researchers who are 
subject to them provide written assurance that they are meeting the 
requirements of the Common Rule. Aside from the assurance process and 
its requirements for reporting violations, “there is no other formal 
mechanism whereby the activities of IRBs are . . . monitored by the 
federal government.”26 Despite the lack of close government oversight, 
there has been considerable success in minimizing human subjects abuse 
since the development of regulations governing IRBs. In fact, following a 
comprehensive review of the regulations as well as data on research 
outcomes, the Presidential Commission for the Study of Bioethical Issues 
recently concluded that “the current U.S. system provides substantial 
protections for the health, rights, and welfare of research subjects and, in 
general, serves to ‘protect people from harm or unethical treatment’ when 
they volunteer to participate as subjects in scientific studies supported by 
 
 
RESEARCH ETHICS 149, 149 (Ezekiel J. Emanuel et al. eds., 2008). It is frequently used in the United 
States as well as other countries to frame discussions about ethical considerations in medical research. 
Id. 
 22. The Belmont Report, U.S. DEP’T OF HEALTH & HUMAN SERVICES, Apr. 18, 1979, 
http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. In providing a historical account of 
the development of The Belmont Report, Tom Beauchamp writes: “The key organizing conception 
underlying the Commission’s presentation of [the] principles and their use was the following: Respect 
for persons applies to informed consent; beneficence applies to risk-benefit assessment; and justice 
applies to the selection of research participants.” Beauchamp, supra note 21, at 150. 
 23. Id. 
 24. Joan P. Porter & Greg Koski, Regulations for the Protection of Humans in Research in the 
United States: The Common Rule, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 156, 
156–57 (Ezekiel J. Emanuel et al. eds., 2008) (referring to regulations later incorporated into 45 C.F.R. 
pt. 46). 
 25. Human Subjects Research Protections: Enhancing Protections for Research Subjects and 
Reducing Burden, Delay, and Ambiguity for Investigators, 76 Fed. Reg. 44512 (proposed July 26, 
2011) (to be codified at 45 C.F.R. pt. 46, 160, 164) [hereinafter ANPRM].  
 26. Jesse A. Goldner, An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously, 38 ST. LOUIS U. L.J. 63, 99–100 (1993). 
Washington University Open Scholarship
  
 
 
 
 
356 WASHINGTON UNIVERSITY GLOBAL STUDIES LAW REVIEW [VOL. 15:351 
 
 
 
 
the federal government.”27 However, a growing number of researchers 
have criticized the IRB process for creating bureaucratic impediments to 
research while providing minimal, if any, ethical protections for human 
subjects.
28
  
B. Globalization of Clinical Research 
The Common Rule remains significantly unchanged since it took effect 
in 1991.
29
 In contrast, the world of biomedical research looks vastly 
different. Funding for federally supported medical research alone nearly 
doubled between 1986 and 1995.
30
 Perhaps most significantly, there has 
been a dramatic increase in the number of research studies performed at 
multiple sites as well as a significant global expansion of biomedical 
research.
31
 For example, the number of publications reporting on 
multicenter studies has increased more than three fold between 1990 and 
1999.
32
 Similarly, the number of countries serving as clinical sites for 
research supported by United States institutions more than doubled 
 
 
 27. Moral Science: Protecting Participants in Human Subjects Research, PRESIDENTIAL 
COMM’N FOR THE STUDY OF BIOETHICAL ISSUES 1, 42 (Dec. 2011), available at http://bioethics.gov/ 
sites/default/files/Moral%20Science%20June%202012.pdf [hereinafter Moral Science 2011]. 
 28. Simon N. Whitney & Carl E. Schneider, Viewpoint: A Method to Estimate the Cost in Lives 
of Ethics Board Review of Biomedical Research, 269 J. INTERNAL MED. 396, 400–01 (2011). See 
generally, George Silberman & Katherine L. Kahn, Burdens on Research Imposed by Institutional 
Review Boards: The State of the Evidence and Its Implications for Regulatory Reform, 89 MILBANK Q. 
599 (2011); Infectious Diseases Society of America, Grinding to a Halt: The Effects of the Increasing 
Regulatory Burden on Research and Quality Improvement Efforts, 49 CLINICAL INFECTIOUS DISEASES 
328 (2009). 
 29. ANPRM, supra note 25. See also Porter & Koski, supra note 24, at 165–66. 
 30. “In the past two decades, phenomenal growth has occurred in federally and industry-
sponsored biomedical research. Federal expenditures for medical and health research conducted in the 
United States and in foreign countries almost doubled from $6.9 billion to $13.4 billion between 1986 
and 1995.” Ethical and Policy Issues in Research Involving Human Participants, NATI’L BIOETHICS 
ADVISORY COUNCIL 4 (Aug. 2001), available at https://bioethicsarchive.georgetown.edu/nbac/ 
human/overvol1.pdf [hereinafter NBAC 2001]. 
 31. See, e.g., Ezekiel J. Emanuel and Jerry Menikoff, Reforming the Regulations Governing 
Research with Human Subjects, 365 NEW ENG. J. MED. 1145 (2011); Rita McWilliams et al., 
Problematic Variation in Local Institutional Review of a Multicenter Genetic Epidemiology Study, 290 
J. AM. MED. ASS’N 360 (2003); Seth W. Glickman et al., Ethical and Scientific Implications of the 
Globalization of Clinical Research, 360 NEW ENG. J. MED. 816 (2009); Institutional Review Boards: A 
Time for Reform, DEP’T OF HEALTH AND HUMAN SERV. 12–13 (June 1998), available at 
www.oig.hhs.gov/oei/reports/oei-01-97-00193.pdf [hereinafter Time for Reform]. 
 32. McWilliams et al., supra note 31, at 362. The authors evaluated results from PubMed to 
identify the number of published multicenter epidemiology studies from 1974 to 2002. The authors 
found that “the number of epidemiology and genetic epidemiology multicenter studies increased 4- to 
5-fold every 5 years during [the period from 1985 to 1999].” Id.  
https://openscholarship.wustl.edu/law_globalstudies/vol15/iss2/8
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between 1995 and 2005.
33
 Furthermore, although a great deal of research 
continues to occur in academic medical centers, studies are now also 
performed outside of academic settings, such as in industry-operated 
centers, community hospitals, and private physicians’ offices.34 IRB 
activity, however, remains largely with academic boards that may have 
little to no experience with non-traditional research environments nor an 
understanding of cultural norms outside of the United States. 
II. CURRENT POLICY AND POTENTIAL REVISIONS 
Current policy governing IRBs and oversight of research involving 
human subjects is codified in the regulations of the Common Rule. Part A 
of this section explains the Common Rule and Part B identifies suggested 
revisions to the regulations.  
A. The Common Rule 
The Common Rule applies to research involving human subjects that is 
conducted, supported, or otherwise subject to regulation by any of the 
federal departments or agencies that have adopted the Rule. Many 
Common Rule provisions directly address the structure and function of 
IRBs. For example, under the regulations an IRB must have at least five 
members including at least one scientist, one non-scientist, and one 
individual who is not affiliated with the institution.
35
 Furthermore, in order 
to approve a study, an IRB must determine that: (1) risks to subjects are 
minimized; (2) the balance between risks to subjects and the anticipated 
benefits are reasonable; (3) selection of research subjects is equitable and 
the needs of vulnerable populations have been considered; (4) subjects 
will receive information that allows them to make an informed choice 
about participation; (5) subjects’ informed consent will be properly 
documented; (6) adequate data monitoring is in place; and (7) the privacy 
and confidentiality of research subjects and their health data will be 
 
 
 33. Glickman et al., supra note 31. Glickman notes that the large populations and lower costs of 
research in countries such as China and India allow researchers to expedite studies that are expanded 
to those regions. In addition, Glickman emphasized that “testing in developing countries is also 
attractive to pharmaceutical and device companies because it can help them overcome regulatory 
barriers for drug approval in these countries in which the population size alone offers the promise of 
expanding markets.” Id. at 817. 
 34. Time for Reform, supra note 31, at 4; Carl H. Coleman, Foreward, 32 SETON HALL L. REV. 
489, 489 (2002). 
 35. 45 C.F.R. § 46.107, infra note 94. 
Washington University Open Scholarship
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maintained.
36
 The Common Rule also provides for an expedited review 
process for research in certain categories
37
 that involves no more than 
minimal risk.
38
 Studies qualifying for expedited review may be reviewed 
and approved by a single member of the IRB–often the chairperson–rather 
than the full board.
39
 
 
 
 36. 45 C.F.R. § 46.111. In full, the regulation provides the criteria for IRB approval of research 
as follows: 
(a) In order to approve research covered by this policy the IRB shall determine that all of the 
following requirements are satisfied: 
 (1) Risks to subjects are minimized: (i) By using procedures which are consistent with 
sound research design and which do not unnecessarily expose subjects to risk, and 
(ii) whenever appropriate, by using procedures already being performed on the subjects for 
diagnostic or treatment purposes. 
 (2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, 
and the importance of the knowledge that may reasonably be expected to result. In evaluating 
risks and benefits, the IRB should consider only those risks and benefits that may result from 
the research (as distinguished from risks and benefits of therapies subjects would receive even 
if not participating in the research). The IRB should not consider possible long-range effects 
of applying knowledge gained in the research (for example, the possible effects of the 
research on public policy) as among those research risks that fall within the purview of its 
responsibility. 
 (3) Selection of subjects is equitable. In making this assessment the IRB should take into 
account the purposes of the research and the setting in which the research will be conducted 
and should be particularly cognizant of the special problems of research involving vulnerable 
populations, such as children, prisoners, pregnant women, mentally disabled persons, or 
economically or educationally disadvantaged persons. 
 (4) Informed consent will be sought from each prospective subject or the subject’s legally 
authorized representative, in accordance with, and to the extent required by § 46.116. 
 (5) Informed consent will be appropriately documented, in accordance with, and to the 
extent required by § 46.117. 
 (6) When appropriate, the research plan makes adequate provision for monitoring the 
data collected to ensure the safety of subjects. 
 (7) When appropriate, there are adequate provisions to protect the privacy of subjects 
and to maintain the confidentiality of data. 
(b) When some or all of the subjects are likely to be vulnerable to coercion or undue 
influence, such as children, prisoners, pregnant women, mentally disabled persons, or 
economically or educationally disadvantaged persons, additional safeguards have been 
included in the study to protect the rights and welfare of these subjects. 
Id. 
 37. Protection of Human Subjects: Categories of Research That May Be Reviewed by the IRB 
through an Expedited Review Procedure, 63 FED. REG. 60,364–67 (1998) [hereinafter Expedited 
Categories]. 
 38. “Minimal risk means that the probability and magnitude of harm or discomfort anticipated in 
the research are not greater in and of themselves than those ordinarily encountered in daily life or 
during the performance of routine physical or psychological examinations or tests.” 45 C.F.R. 
§ 46.102. 
 39. 45 C.F.R. § 46.110. 
(a) The Secretary, HHS, has established, and published as a Notice in the Federal Register, a 
list of categories of research that may be reviewed by the IRB through an expedited review 
procedure. The list will be amended, as appropriate after consultation with other departments 
https://openscholarship.wustl.edu/law_globalstudies/vol15/iss2/8
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Although the regulations that make up the Common Rule have 
remained largely unchanged for decades, and have been successful in 
promoting ethical human research, criticism of the regulations abound.
40
 In 
response to these criticisms, as well as suggested reforms by the National 
Bioethics Advisory Commission and the Institute of Medicine, DHHS 
convened a working group to consider revisions to the Common Rule.
41
 
DHHS published the group’s work in the Federal Register in July 2011 as 
an Advanced Notice of Proposed Rulemaking (ANPRM).  
B. Advanced Notice of Proposed Rulemaking (ANPRM) 
The ANPRM identified seven areas for potential reform and solicited 
public comment on whether and how the Rule should be changed.
42
 The 
 
 
and agencies, through periodic republication by the Secretary, HHS, in the Federal Register. 
A copy of the list is available from the Office of Human Research Protections, HHS, or any 
successor office. 
(b) An IRB may use the expedited review procedure to review either or both of the following: 
 (1) Some or all of the research appearing on the list and found by the reviewer(s) to 
involve no more than minimal risk, 
 (2) Minor changes in previously approved research during the period (of one year or less) 
for which approval is authorized. Under the expedited review procedure, the review may be 
carried out by the IRB chairperson or by one or more experienced reviewers designated by 
the chairperson from among members of the IRB. In reviewing the research, the reviewers 
may exercise all of the authorities of the IRB except that the reviewers may not disapprove 
the research. A research activity may be disapproved only after review in accordance with the 
non-expedited procedure set forth in § 46.108(b). 
(c) Each IRB which uses an expedited review procedure shall adopt a method for keeping all 
members advised of research proposals which have been approved under the procedure. 
(d) The department or agency head may restrict, suspend, terminate, or choose not to 
authorize an institution’s or IRB’s use of the expedited review procedure.  
Id.  
 40. Critics cite unjustified costs and burdens associated with redundant review of multicenter 
research studies by multiple IRBs, IRB review of research activities that are outside of the scope of 
biomedical research, and IRBs’ increased focus on improving readability of informed consent 
documentation while only making forms longer and less intelligible. Steven Joffe, Revolution or 
Reform in Human Subjects Research Oversight, 40 J.L. MED. & ETHICS 922, 923 (2012); Scott Kim, 
Peter Ubel, & Raymond DeVries, Pruning the Regulatory Tree, 457 NATURE 534, 534–35 (2009); 
Norman Fost & Robert J. Levine, The Dysregulation of Human Subjects Research, 298 NATURE 2196, 
2196–97 (2007); see generally The Illinois White Paper: Improving the System for Protecting Human 
Subjects: Counteracting IRB “Mission Creep,” CENTER FOR ADV. STUD. (2005), available at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=902995 (last visited Sept. 17, 2015); Ezekiel J. 
Emanuel et al., Oversight of Human Participants Research: Identifying Problems to Evaluate Reform 
Proposals, 141 ANNALS OF INTERNAL MED. 282 (2004). 
 41. ANPRM, supra note 25, at 44512–13; NBAC 2001, supra note 22; RESPONSIBLE RESEARCH: 
A SYSTEMS APPROACH TO PROTECTING RESEARCH PARTICIPANTS (Daniel D. Federman et al. eds., 
2002) [hereinafter IOM 2002]. 
 42. ANPRM, supra note 25. The ANPRM considered the following seven changes to the 
regulatory framework:  
Washington University Open Scholarship
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ANPRM identified four areas for reform with particular relevance to 
IRBs: (1) a need to better calibrate the degree of research oversight to the 
degree of risk posed by the research; (2) a need to eliminate redundancy of 
IRB review in multicenter domestic studies; (3) a need to improve the 
process of obtaining informed consent; and (4) a need to expand federal 
oversight of human subjects research to privately funded studies.
43
 The 
ANPRM will be followed by a notice of proposed rulemaking to identify 
the proposed regulations and another period for public consideration and 
comment before any changes are made. 
1. Ensuring Risk-Based Protections 
The current regulations divide human research studies into one of three 
oversight categories: exempt, expedited review, or convened IRB review.
44
 
Studies exempt from review include those involving the use of educational 
tests or existing data so long as a subject’s identifiable information is not 
linked to data.
45
 Studies that fall into one of several categories
46
 and 
 
 
(1) Refinement of the existing risk-based regulatory framework; (2) Utilization of a single 
IRB review of record for domestic sites of multi-site studies; (3) Improvement of consent 
forms and the consent process; (4) Establishment of mandatory data security and information 
protection standards for all studies that involve identifiable or potentially identifiable data; 
(5) Establishment of an improved, more systematic approach for the collection and analysis of 
data on unanticipated problems and adverse events; (6) Extension of federal regulatory 
protections to all research, regardless of funding source, conducted at institutions in the U.S. 
that receive some federal funding from a Common Rule agency for research with human 
subjects; and (7) Improvement in the harmonization of regulations and related agency 
guidance. 
Id. at 44514. 
 43. ANPRM, supra note 25, at 44514. 
 44. Id. 
 45. 45 C.F.R. § 46.101(b). The regulation stipulates that: 
(b) Unless otherwise required by department or agency heads, research activities in which the 
only involvement of human subjects will be in one or more of the following categories are 
exempt from this policy: 
 (1) Research conducted in established or commonly accepted educational settings, 
involving normal educational practices, such as (i) research on regular and special education 
instructional strategies, or (ii) research on the effectiveness of or the comparison among 
instructional techniques, curricula, or classroom management methods. 
 (2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, 
achievement), survey procedures, interview procedures or observation of public behavior, 
unless:(i) Information obtained is recorded in such a manner that human subjects can be 
identified, directly or through identifiers linked to the subjects; and (ii) any disclosure of the 
human subjects’ response outside the research could reasonably place the subjects at risk of 
criminal or civil liability or be damaging to the subjects’ financial standing, employability, or 
reputation. 
 (3) Research involving the use of educational tests (cognitive, diagnostic, aptitude, 
achievement), survey procedures, interview procedures, or observation of public behavior that 
https://openscholarship.wustl.edu/law_globalstudies/vol15/iss2/8
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involve no more than minimal risk to the human subject
47
 may qualify for 
expedited review.
48
 A study that qualifies for expedited review can be 
reviewed by a single designated IRB member who acts in place of the 
board.
49
  
Currently, the majority of research studies involving human subjects 
must undergo review by a convened IRB. To be approved, a study must 
 
 
is not exempt under [(2)] of this section, if:(i) The human subjects are elected or appointed 
public officials or candidates for public office; or ii) federal statute(s) require(s) without 
exception that the confidentiality of the personally identifiable information will be maintained 
throughout the research and thereafter. 
 (4) Research, involving the collection or study of existing data, documents, records, 
pathological specimens, or diagnostic specimens, if these sources are publicly available or if 
the information is recorded by the investigator in such a manner that subjects cannot be 
identified, directly or through identifiers linked to the subjects. 
 (5) Research and demonstration projects which are conducted by or subject to the 
approval of department or agency heads, and which are designed to study, evaluate, or 
otherwise examine:(i) Public benefit or service programs; (ii) procedures for obtaining 
benefits or services under those programs; (iii) possible changes in or alternatives to those 
programs or procedures; or (iv) possible changes in methods or levels of payment for benefits 
or services under those programs. 
 (6) Taste and food quality evaluation and consumer acceptance studies, (i) if wholesome 
foods without additives are consumed or (ii) if a food is consumed that contains a food 
ingredient at or below the level and for a use found to be safe, or agricultural chemical or 
environmental contaminant at or below the level found to be safe, by the Food and Drug 
Administration or approved by the Environmental Protection Agency or the Food Safety and 
Inspection Service of the U.S. Department of Agriculture. 
Id. 
 46. There are currently nine categories of research that are eligible for expedited review. They 
include, for example, research that involves collecting small amounts of blood from healthy, non-
pregnant adults and research that utilizes certain noninvasive clinical procedures such as magnetic 
resonance imaging. For complete list, see Expedited Categories, supra note 37.  
 47. See supra note 38 for the Common Rule definition of minimal risk.  
 48. 45 CFR § 46.110; Expedited Categories, supra note 37. The Common Rule specifies: 
 An IRB may use the expedited review procedure to review either or both of the 
following: (1) Some or all of the research appearing on the list [of categories of research that 
may be eligible for expedited review] and found by the reviewer(s) to involve no more than 
minimal risk, (2) Minor changes in previously approved research during the period (of one 
year or less) for which approval is authorized.  
 Under an expedited review procedure, the review may be carried out by the IRB 
chairperson or by one or more experienced reviewers designated by the chairperson from 
among members of the IRB. In reviewing the research, the reviewers may exercise all of the 
authorities of the IRB except that the reviewers may not disapprove the research. A research 
activity may be disapproved only after review in accordance with the non-expedited 
procedure set forth in § 46.108(b). 
 Each IRB which uses an expedited review procedure shall adopt a method for keeping all 
members advised of research proposals which have been approved under the procedure. 
45 CFR § 46.110(b),(c). 
 49. The designated member who reviews research proposals qualifying for expedited review may 
be the chairperson or another experienced reviewer who is on the IRB. 45 CFR § 46.110(b). 
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receive the votes of a majority of the board.
50
 The ANPRM contemplates 
maintaining the requirement of review by a convened IRB for research 
involving more than minimal risk.
51
 But the ANPRM contemplates 
expanding the number of research projects that qualify for expedited 
review.
52
 Furthermore, the ANPRM considers reducing the paperwork 
required for expedited review.
53
 Officials could also provide templates of 
protocols and consent documents for common types of studies that 
researchers could adapt.
54
 Finally, the ANPRM contemplates expanding 
the category of research activities that qualify as exempt (referred to as 
“excused” in the ANPRM).55  
2. Streamlining IRB Review of Multicenter Studies 
Under current regulations, the IRBs in each institution participating in 
a multicenter study must approve the study.
56
 Multiple institutions 
participating in the same study frequently have their own IRBs review the 
study protocol and consent documents.
57
 To avoid duplicative efforts that 
do not contribute additional safeguards to human subjects, the ANPRM 
contemplates a change in the Common Rule that would require institutions 
participating in multicenter studies to select a single IRB as the IRB of 
record.
58
 The proposed change would apply to studies conducted 
exclusively in the United States that do not require FDA approval.
59
 
 
 
 50. According to the Common Rule, IRBs must “review proposed research at convened meetings 
at which a majority of the members of the IRB are present, including at least one member whose 
primary concerns are in nonscientific areas. In order for the research to be approved, it shall receive 
the approval of a majority of those members present at the meeting.” 45 CFR § 46.108(b). 
 51. No continuing annual review would be required if the ongoing research was limited to review 
of existing data. ANPRM, supra note 25, at 44516. 
 52. To accomplish this goal, federal officials would routinely reassess and update the list of 
research activities that qualify for expedited review. They would also revise the regulations to include 
a presumption that research studies involving activities on the list present minimal risk and thus 
qualify for expedited review. Id. 
 53. Id. at 44517. 
 54. Id. 
 55. Id. at 44518. The exempt category would be expanded by exempting research on 
biospecimens or existing data even if the data or specimens are linked to identifying information. Id. at 
44, 519. 
 56. However, studies may be reviewed jointly for two institutions by one IRB. 45 CFR § 46.114. 
 57. ANPRM, supra note 25, at 44521–22; Joffe, supra note 40, at 923.  
 58. ANPRM, supra note 25, at 44522. 
 59. The ANPRM notes that the change is being considered only for domestic sites in multicenter 
studies as “independent local IRB reviews of international sites are appropriate because it might be 
difficult for an IRB in the U.S. to adequately evaluate local conditions in a foreign country that would 
play an important role in the ethical evaluation of the study.” Id. at 44521–22. 
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3. Improving Informed Consent 
Currently, under the Common Rule, researchers must obtain and 
document that they have obtained informed consent from a subject before 
research involving that subject can commence.
60
 Furthermore, the consent 
process and associated forms used by researchers must be reviewed and 
approved by an IRB. Although only minor changes have been made to the 
regulations concerning informed consent in the past forty years, 
commentators have noted that during that same period the informed 
consent forms presented to potential subjects have gotten longer and IRBs 
have spent considerably more time reviewing them without improving the 
ability to obtain actual informed consent.
61
 The ANPRM acknowledges 
 
 
 60. 45 CFR § 46.116. The regulations currently require that the documents used to obtain a 
subject’s consent include the following information: 
(1) A statement that the study involves research, an explanation of the purposes of the 
research and expected duration of the subject’s participation, a description of the procedures 
to be followed, and identification of any procedures which are experimental; 
(2) A description of any reasonably foreseeable risks or discomforts to the subject; 
(3) A description of any benefits to the subject or to others which may reasonably be expected 
from the research; 
(4) A disclosure of appropriate alternative procedures or courses of treatment, if any, that 
might be advantageous to the subject; 
(5) A statement describing the extent, if any, to which confidentiality of records identifying 
the subject will be maintained;  
(6) For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treatments are available if injury 
occurs and, if so, what they consist of, or where further information may be obtained; 
(7) An explanation of whom to contact for answers to pertinent questions about the research 
and research subjects’ rights, and whom to contact in the event of a research-related injury to 
the subject; and 
(8) A statement that participation is voluntary, refusal to participate will involve no penalty or 
loss of benefits to which the subject is otherwise entitled, and the subject may discontinue 
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled. 
Id. 
 61. See generally Ilene Albala, Margaret Doyle, & Paul S. Appelbaum, The Evolution of Consent 
forms for Research: A Quarter Century of Changes, 32 IRB: ETHICS & HUM. RESEARCH 7 (2010); 
William Burman et al., The Effects of Local Review on Informed Consent Documents from a 
Multicenter Clinical Trials Consortium, 24 CONTROLLED CLIN. TRIALS 245 (2003); Jerry Menikoff & 
Edward P. Richards, What the Doctor Didn’t Say: The Hidden Truth about Medical Research 113–23 
(2006); Carl E. Schneider, The Hydra, 40 HASTINGS CTR. REP. 9 (2010). Results of a study performed 
by William Burman and colleagues illustrates the problem. Burman’s study evaluated the review 
process of two protocols from a multicenter study that was reviewed separately by twenty-five 
different local IRBs. The study found that IRB “review was a time-consuming process, requiring a 
median of 30 hours of work by the local study site and more than 3 months of calendar time to 
complete.” William Burman, et al. supra at 251. Although the IRBs did not require changes in the 
protocols, they did require a median of 46.5 changes in each consent form. Id. at 245. The authors 
concluded that only 1.5% of those changes “were thought to represent a need to fit specific local 
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that the current “[l]ength and high reading levels [of informed consent 
forms] may inhibit people from reading the full document and 
understanding relevant information.”62 As a result, the ANPRM 
contemplates changes to the regulations that would specifically identify 
content to be included in the consent forms—in part through making 
template consent forms available to researchers—and also limit the length 
of certain sections of the documents.
63
 In addition, the ANPRM 
contemplates changes to the Common Rule that would expand the 
conditions under which the requirements for informed consent could be 
waived.
64
 In particular, the ANPRM notes that criteria for obtaining a 
waiver under the present regulations may not permit researchers to obtain 
waivers under circumstances where they are seeking to conduct research 
on persons whose culture or customs disfavor having individuals sign 
 
 
conditions.” Id. at 249. Furthermore, although the majority of the changes did not alter the substance 
of the consent forms they did effect their quality. Following the changes the forms were longer, 
sentences were wordier and the authors found that the overall reading level was higher than before the 
changes. They reported that after the IRB-required changes 41% of the forms “had an inappropriately 
high reading grade level.” Id. 
 62. ANPRM, supra note 25, at 44522. 
 63. Id. at 44523. 
We are considering a number of modifications to the regulations to improve consent forms, 
including (1) prescribing appropriate content that must be included in consent forms, with 
greater specificity than is provided in the current regulations; (2) restricting content that 
would be inappropriate to include in consent forms; (3) limiting the acceptable length of 
various sections of a consent form; (4) prescribing how information should be presented in 
consent forms, such as information that should be included at the very beginning of the 
consent form, or types of information that should be included in appendices and not in the 
main body of the consent form; (5) reducing institutional “boilerplate” in consent forms (that 
is, standard language that does little to genuinely inform subjects, and often is intended to 
primarily protect institutions from lawsuits); and (6) making available standardized consent 
form templates, the use of which could satisfy applicable regulatory provisions. 
Id. 
 64. Currently, an IRB may waive the requirement to obtain informed consent if the IRB 
determines that the research will be conducted by or subject to government approval; is designed to 
“study, evaluate, or otherwise examine . . . public benefit of service programs,” or procedures, services 
or possible changes to such programs; AND “[t]he research could not practically be carried out 
without the waiver . . .” 45 CFR § 46.116(c). Waiver of informed consent is more commonly obtained 
by satisfying the requirements of 45 CFR § 46.116(d): 
An IRB may approve a consent procedure which does not include, or which alters, some or all 
of the elements of informed consent set forth in this section, or waive the requirements to 
obtain informed consent provided the IRB finds and documents that: 
(1) The research involves no more than minimal risk to the subjects; 
(2) The waiver or alteration will not adversely  
affect the rights and welfare of the subjects; 
(3) The research could not practicably be carried out without the waiver or alteration; and  
(4) Whenever appropriate, the subjects will be provided with additional pertinent information 
after participation.  
Id. 
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documents.
65
 To address this concern the ANPRM requests comments and 
suggestions regarding “. . . circumstances under which it should be 
permissible to waive the usual requirements for obtaining or documenting 
informed consent.”66 
4. Expanding Federal Regulations 
At present, the federal regulations governing the review of human 
subjects research apply only to research that is supported or conducted by 
a federal department or agency that has adopted them.
67
 However, the 
Food and Drug Administration (FDA) also applies much of the Common 
Rule to privately funded research on drugs and devices seeking FDA 
approval.
68
 As the ANPRM notes, most institutions voluntarily require 
IRB approval for research that is not supported by federal funds, but such 
approval is not currently a federal requirement.
69
 The ANPRM 
contemplates a new regulation requiring IRB review for all research 
involving human subjects at the institutions that receive any federal 
support.
70
 The ANPRM points to support for legislation that would expand 
 
 
 65. ANPRM, supra note 25, at 44523. The ANPRM notes that: 
The current criteria for such a waiver may not be flexible enough for dealing with a variety of 
circumstances, such as when Federally-sponsored research is conducted in an international 
setting where for cultural or historical reasons signing documents may be viewed as offensive 
or problematic. 
Id. 
 66. Id. 
 67. The regulation specifies: 
(a) Except as provided in paragraph (b) of this section, this policy applies to all research 
involving human subjects conducted, supported or otherwise subject to regulation by any 
federal department or agency which takes appropriate administrative action to make the 
policy applicable to such research. This includes research conducted by federal civilian 
employees or military personnel, except that each department or agency head may adopt such 
procedural modifications as may be appropriate from an administrative standpoint. It also 
includes research conducted, supported, or otherwise subject to regulation by the federal 
government outside the United States. 
 (1) Research that is conducted or supported by a federal department or agency, whether 
or not it is regulated as defined in § 46.102(e), must comply with all sections of this policy. 
 (2) Research that is neither conducted nor supported by a federal department or agency 
but is subject to regulation as defined in § 46.102(e) must be reviewed and approved, in 
compliance with § 46.101, § 46.102, and § 46.107 through § 46.117 of this policy, by an 
institutional review board (IRB) that operates in accordance with the pertinent requirements 
of this policy. 
45 CFR § 46.101(a). 
 68. See 21 CFR §§ 50, 56, 312, 812.  
 69. ANPRM, supra note 25, at 44528. 
 70. Id. 
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research oversight to all human subjects research conducted in the United 
States, regardless of funding source.
71
 
III. CURRENT RESEARCH REVIEW SYSTEM CONTROVERSIES 
The potential changes to the Common Rule presented in the ANPRM 
represent federal officials’ ideas for making IRBs more efficient and 
effective in applying ethical principles to human subjects research. 
Although the ANPRM addressed many criticisms of the federal research 
oversight system, it ultimately suggested fairly conservative reforms, 
leaving important controversies untouched.
72
 Some commentators have 
advocated for more substantial changes. In a 2009 commentary, research 
ethicist Scott Kim and his colleagues argued for exempting all minimal 
risk research from IRB oversight.
73
 Other scholars contend that the current 
system has fundamental yet remediable flaws that the ANPRM did not 
consider.
74
 This part of the note considers examples of such concerns. 
A.  Prospective Versus Retrospective Review 
In a 2012 commentary, research ethicists Robert Klitzman and Paul 
Appelbaum argue that a retrospective or audit-type review would be a 
more effective system for research oversight than the current prospective 
system.
75
 The authors contend, since reviewers under a prospective system 
can evaluate only what researchers propose to do, reviewers will 
inevitably focus on relatively unimportant details like the wording of 
consent forms.
76
 According to Klitzman and Appelbaum, applying 
prospective review to research oversight undermines the purpose of the 
system. In contrast, the authors suggest that using a retrospective or audit-
type review would allow both reviewers and researchers to shift their 
 
 
 71. Id.; NBAC 2001, supra note 30, at 28. 
 72. See ANPRM, supra note 25. 
 73. Kim et al., supra note 40. Others have argued that problems with the human research 
oversight system are unfixable and even that the current system is unconstitutional. See Simon N. 
Whitney & Carl E. Schneider, Was the Institutional Review Board System a Mistake?, 49 CLINICAL 
INFECTIOUS DISEASES 1957 (2009); Philip Hamburger, Getting Permission, 101 NW. U. L. REV. 405 
(2007). 
 74. Charles W. Lidz & Suzanne Garverich, What the ANPRM Missed: Additional Needs for IRB 
Reform, 41 J.L. MED. & ETHICS 390 (2013). 
 75. Robert Klitzman & Paul S. Appelbaum, To Protect Human Subjects, Review What Was 
Done, Not Proposed, 335 SCIENCE 1576 (2012). 
 76. “Because prospective review can only focus on what researchers say they will do, IRBs 
inevitably concentrate most of their attention on the minutiae of protocols and consent forms rather 
than on monitoring actual performance.” Id. at 1576. 
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focus in ways that are more likely to benefit human subjects. Researchers 
would simply register their studies with IRBs rather than seek IRB 
approval before commencing the research.
77
 IRBs could randomly audit 
protocols to ensure that researchers were complying with requirements to, 
for example, obtain informed consent from subjects, protect subjects’ 
personal health information, and properly characterize research as 
involving more-than-minimal risk or no-more-than minimal risk.
78
 
Klitzman and Appelbaum further argue that a retrospective system will 
provide more incentives for researchers to ascertain, for example, that 
subjects are truly providing voluntary, informed consent since their 
research might be audited at any time.
79
 In addition, the ethicists propose 
that moving to a retrospective system of ethics review would provide an 
opportunity to create an appellate IRB process which would improve 
efficiency and fairness of the system.
80
  
By comparison, Alex London argues that a prospective review system 
provides researchers with incentives to submit only their most polished 
protocols.
81
 Thus, according to London, the fact that reviewers end up 
spending time contemplating word choice in submitted documents only 
supports the notion that a prospective review system efficiently protects 
human subjects. The documents submitted to the IRB, London 
emphasizes, “already reflect the influence of the regulatory regime.”82 
London contends that studies subject only to a retrospective review system 
 
 
 77. Id. at 1577. 
 78. Id. The authors further point out that some institutions have already implemented audit-type 
reviews of research studies and thus there is already some experience with the model. Adapting 
prospective review requirements, they contend, will be detrimental to progress. “Grafting some degree 
of retrospective review onto the current process would not address the system’s inefficiencies, 
including the work and delay inherent in universal prospective review, the undue weight given to 
written descriptions of procedures rather than actual researcher behavior, and the emphasis on 
speculative outcomes.” Id. 
 79. Id. Klitzman and Appelbaum write that: 
At present, once a study is approved by an IRB, an investigator is generally not required to 
monitor or improve the effectiveness of the consent process or subjects’ reactions to 
participation. But the possibility of being audited on the basis of how well subjects 
understood the study or whether they were distressed by the research procedures—based on 
objective, validated questionnaires—would provide different incentives. 
Id. 
 80. Id. The ethicists note that “[a]lthough an appeals process could be constructed in a 
prospective review system, a retrospective system would allow determinations based on evidence of 
what actually occurred, rather than fears of what might happen. That difference may increase 
researcher willingness to pursue an appeals process.” Id. 
 81. Alex J. London, A Non-Paternalistic Model of Research Ethics and Oversight: Assessing the 
Benefits of Prospective Review, 40 J.L. MED. & ETHICS 930, 937 (2012). 
 82. Id. 
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would lack the quality assurance that gives the public confidence in 
research and would thus result in a decrease in research participation.
83
 
In a separate criticism reviewing twenty IRB panels, Charles Lidz and 
Suzanne Garverich observed that reviewers never simply accept proposals 
as written but will request some changes even if such changes don’t 
substantively change the proposal.
84
 The more that reviewers focus on and 
find fault with details such as wording on forms, the argument goes, the 
more time and effort researchers will spend on revising their documents 
for IRB review rather than ensuring that potential subjects truly 
understand the purpose of the study, for example. 
B. Analogical Reasoning and IRBs 
In a 2004 law review article, Professor Carl Coleman suggests that 
IRBs could benefit from assessing research study protocols in a manner 
similar to common law reasoning by identifying relevant features of a 
study under consideration, finding prior studies with similar features, and 
then evaluating similarities and differences between the studies to 
determine whether the approach taken previously should be used in the 
study under consideration.
85
 Coleman identifies a number of potential 
benefits to IRBs employing such an analogical approach: improving 
members’ exercise of discretion, reducing the inconsistency of IRB 
evaluations, providing a general framework for evaluating new research 
studies and identifying best methods for risk reduction.
86
 Thus, requiring 
IRBs to consider evaluations rendered by other IRBs will inherently 
enhance the diversity of reviewers assessing any given study.  
 
 
 83. Id. at 939.  
 84. Lidz & Garverich, supra note 74, at 392.  
[P]rotocol reviewers never say: “There is nothing that needs to be changed about this 
proposal.” In fact, such a review would be quite surprising because reviewers are expected to 
find problems. A reviewer who made such a comment would appear either not to have done 
the required review, or not to be very thoughtful and thorough in the analysis. 
Id. 
 85. Carl H. Coleman, Rationalizing Risk Assessment in Human Subjects Research, 46 ARIZ. L. 
REV. 1, 28 (2004). 
 86. Id. at 34–36. Fundamentally, Coleman notes, the use of analogical reasoning “would 
necessarily broaden the range of perspectives incorporated into the IRB’s analysis.” Id. at 34. 
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C. Facilitating Ethical Research 
Some critics of the current research oversight system contend that IRBs 
spend so much time and effort achieving compliance with federal 
regulations that they contribute—albeit indirectly—to unethical behavior 
by researchers.
87
 Spellecy and May report that clinical researchers who 
admit to omitting information or engaging in other forms of deception 
when interacting with IRBs cited as reasons long review times and “lack 
of clarity and/or controversy about what should be subject to IRB 
review.”88 The authors suggest that as IRBs spend considerable time re-
wording consent forms and optimizing protocols not for the purpose of 
enhancing protection of human subjects but simply to improve study 
design, they inherently contribute to the unpredictability that undermines 
the legitimacy of their role in the eyes of some researchers.
89
  
Similarly, in their study of twenty IRB panels at ten medical 
institutions, Lidz and Garverich observed that IRBs spent significant time 
discussing design methods to the exclusion of discussions on research 
ethics.
90
 In fact, the study data revealed IRB lapses including a failure to 
discuss risk minimization in 21% of protocols involving more-than-
minimal risk to human subjects.
91
 Spellecy and May argue that IRBs 
should not consider themselves simply protectors of human research 
subjects—a conclusion that may encourage creating impediments to 
research since “research not undertaken poses no threat of harm to 
[subjects]”—but as facilitators of ethical research.92 A shift in emphasis of 
the IRB role to one of facilitator, they contend, would eliminate a 
 
 
 87. Ryan Spellecy & Thomas May, More Than Cheating: Deception, IRB Shopping, and the 
Normative Legitimacy of IRBs, 40 J.L. MED. & ETHICS 990, 994 (2012). 
 88. Id. at 990 (citing Jim Giles, Researchers Break Rules in Frustration at Review Boards, 438 
NATURE 136 (2005); Brian C. Martinson, Melissa S. Anderson, & Raymond DeVries, Scientists 
Behaving Badly, 435 NATURE 737 (2005)).  
 89. Spellecy, supra note 87, at 991. 
 90. Lidz & Garverich, supra note 74, at 394. While acknowledging the limitations of 
observational research, the authors noted that: 
[W]e do know from our study that IRBs tend to spend a lot of their time discussing the 
appropriateness of the design and the methods of the studies that were reviewed. For example, 
15.9% of the speaking turns (i.e., any time a person at the meeting says anything, we counted 
one speaking turn and coded it for one or more topics that the speaker discussed) in these full 
board meetings involved discussion of methodological issues. The academic scientists who 
largely populated the IRB panels we observed often discussed the scientific issues to the 
exclusion of research ethics; in brief, concerns about the science sometimes diverted attention 
away from reviewing ethics. 
Id. 
 91. Id. at 393–95. 
 92. Spellecy, supra note 87, at 994. 
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presumption of inadequacy that the IRB might otherwise hold about the 
research protocol.
93
 Furthermore, identifying IRBs as ethical research 
facilitators would re-direct members’ focus to the Common Rule’s central 
mandates for IRB oversight, including risk minimization and risk/benefit 
assessment.  
D. Community Representation on IRBs 
The Common Rule requires that an IRB be made up of members “with 
varying backgrounds to promote complete and adequate review of 
research activities.” (emphasis added).94 The regulation further specifies 
that “[t]he IRB shall be sufficiently qualified . . . to promote respect for its 
advice and counsel in safeguarding the rights and welfare of human 
subjects” and requires that at least one of the members be a nonscientist, 
one a scientist, and one a person unaffiliated with the institution.
95
 In the 
 
 
 93. Id. at 994. 
 94. 45 CFR § 46.107. The regulation specifies: 
(a) Each IRB shall have at least five members, with varying backgrounds to promote 
complete and adequate review of research activities commonly conducted by the institution. 
The IRB shall be sufficiently qualified through the experience and expertise of its members, 
and the diversity of its members, including consideration of race, gender, and cultural 
backgrounds and sensitivity to such issues as community attitudes, to promote respect for its 
advice and counsel in safeguarding the rights and welfare of human subjects. In addition to 
possessing the professional competence necessary to review specific research activities, the 
IRB shall be able to ascertain the acceptability of proposed research in terms of institutional 
commitments and regulations, applicable law, and standards of professional conduct and 
practice. The IRB shall therefore include persons knowledgeable in these areas. If an IRB 
regularly reviews research that involves a vulnerable category of subjects, such as children, 
prisoners or pregnant women, or handicapped or mentally disabled persons, consideration 
shall be given to the inclusion of one or more individuals who are knowledgeable about and 
experienced in working with these subjects. 
(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of 
men or entirely of women, including the institution’s consideration of qualified persons of 
both sexes, so long as no selection is made to the IRB on the basis of gender. 
(c) Each IRB shall include at least one member whose primary concerns are in scientific areas 
and at least one member whose primary concerns are in nonscientific areas. 
(d) Each IRB shall include at least one member who is not otherwise affiliated with the 
institution and who is not part of the immediate family of a person who is affiliated with the 
institution. 
(e) No IRB may have a member participate in the IRB’s initial or continuing review of any 
project in which the member has a conflicting interest, except to provide information 
requested by the IRB. 
(f) An IRB may, in its discretion, invite individuals with the competence in special areas to 
assist in the review of issues which require expertise beyond or in addition to that available on 
the IRB. These individuals may not vote with the IRB. 
Id. 
 95. Id. 
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case of IRBs in academic settings, there is frequently only one unaffiliated 
member—sometimes referred to as a community member—on a board of 
fifteen to twenty people that is not affiliated with the institution.
96
 The 
National Bioethics Advisory Commission (NBAC) acknowledged 
concerns about the disparity in community representation and others have 
noted that inclusion of more community members is necessary in order to 
increase transparency.
97
 Although an unaffiliated member must be on the 
IRB, under current regulations that member’s absence does not prohibit 
quorum from being met as long as a nonscientist is present.
98
 Thus, IRBs 
can review and approve research with only institutional representation.  
Other commentators have proposed requiring that more than one 
unaffiliated member be on an IRB and that at least one unaffiliated 
member be present in order for there to be a quorum.
99
 NBAC emphasized 
that the greater the number of unaffiliated members on an IRB the less 
likely it would be that an institutional conflict would persist.
100
 NBAC 
further urged that research subjects be represented on the IRB. The group 
cautioned that unaffiliated and nonscientist members may not represent the 
interests of subjects any better than scientists from the institution.
101
 
NBAC ultimately recommended that at least 25% of an IRB’s membership 
be collectively made up of unaffiliated members, nonscientists, and 
subject representatives.
102
 Increasing the percentage of nonscientists and 
unaffiliated members would be significant since psychological studies 
have established that a social effect exists such that members of a group 
 
 
 96. In the case of independent IRBs, nearly all members will be unaffiliated with the institution. 
For the purposes of regulatory interpretation, the corporation administering the independent IRB is an 
institution. Angela J. Bowen, Models of Institutional Review Board Function, in THE OXFORD 
TEXTBOOK OF CLIN. RESEARCH ETHICS 552, 554 (Ezekiel J. Emanuel et al. eds., 2008); David Forster, 
Independent Institutional Review Boards, 32 SETON HALL L. REV. 513, 513 (2002). 
 97. NBAC 2001, supra note 30, at 62; Bowen, supra note 96, at 554. 
 98. NBAC 2001, supra note 30, at 62. 
 99. Time for Reform, supra note 31, at 17–18. 
 100. “Conflicts affecting the IRB can be handled by increasing the percentage of members who do 
not have any direct interests in the institution. . . . Increasing the percentage of nonscientists and 
members who represent the views of participants can also reduce conflicts.” NBAC 2001, supra note 
30, at 64. NBAC further noted that use of independent or fee-for-service IRBs would practically 
eliminate institutional conflict concerns. Id. at 62. 
 101. Id. at 63. 
The current IRB system requires that unaffiliated and nonscientist members serve on these 
groups. Although each brings valuable experience, knowledge, and insight to the IRB, neither 
may reflect the views of the research participants. For this reason, IRBs should include 
members who are specifically chosen because they represent participants’ interests. 
Id. 
 102. Id. at 64. 
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will speak up more assertively if they believe someone else in the group 
shares their viewpoint.
103
 
E. U.S. Regulations and Ethical Imperialism 
Although U.S. federal regulations require that research using federal 
funds must be reviewed by an IRB that has been approved by the U.S. 
Office for Human Research Protections (OHRP), the CIOMS International 
Ethical Guidelines require that research conducted by investigators outside 
of their home country be reviewed by RECs in both countries.
104
 Some 
commentators contend that U.S. regulations should mirror the CIOMs 
guidelines and require ethical review in the country where the research is 
conducted as well as in the U.S.
105
 Others argue that approval of research 
protocols by a U.S. IRB should be sufficient, and still others argue that an 
REC in the country where the research is conducted should suffice. The 
views represent a variety of opinions about how flexible regulations 
should be concerning research that is conducted outside of the country 
where it is sponsored. Some commentators contend that requiring strict 
adherence to U.S. rules is an example of ethical imperialism in the conduct 
of research.
106
 
In 2002, OHRP issued new rules for non-U.S. institutions seeking 
authorization as sites for research conducted by U.S. researchers or others 
using U.S. federal funds. The authorization program is called the 
Federalwide Assurance for International (non-U.S.) Institutions. The 
foreign institution must indicate on the application whether the 
 
 
 103. Ivor A. Pritchard, How Do IRB Members Make Decisions? A Review and Research Agenda, 
6 J. EMPIRICAL RES. ON HUM. RESEARCH ETHICS 31, 38 (2011). Pritchard identifies what he calls 
“social proof” as a source by which members of a group come to agreement: 
If people see that other people are doing something, they tend to believe that behavior is 
correct or socially acceptable. In IRB meetings, during the discussion of a research proposal 
or in the actual voting process, one or more IRB members may indicate how they will vote on 
the decision at hand . . . once that happens, the other members are in a position where they 
now can vote the same way, because doing so appears to be acceptable. 
Id. 
 104. Macklin, supra note 2, at 716. 
 105. Daniel W. Fitzgerald, Angela Wasunna, & Jean William Pape, Ten Questions Institutional 
Review Boards Should Ask when Reviewing International Clinical Research Protocols, 25 IRB: 
ETHICS & HUM. RESEARCH 14, 14–15 (2003). 
 106. Id.; In a study commissioned by NBAC, 77% of U.S. researchers surveyed and 85% of 
researchers in developing countries who were surveyed recommended the use of international 
guidelines instead of U.S. regulations to cover joint projects. National Bioethics Advisory Council, 
Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries 82 
(2001), https://bioethicsarchive.georgetown.edu/nbac/clinical/Vol1.pdf [hereinafter NBAC International 
2001]. 
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Declaration of Helsinki or some other statement of ethical principles 
governs it in protecting the rights and welfare of human subjects involved 
in research.
107
 Adherence to a statement of ethical principles is not 
sufficient, however. The institution applying for authorization also must 
comply with U.S. regulations or with alternative regulatory standards that 
are consistent with the U.S. Common Rule.
108
 Additional questions 
surround the mechanism of ethics committee review. For example, when 
research protocols are reviewed by an IRB in the U.S. and an REC in the 
country where the research is to be conducted, how should any 
disagreements between the committees be resolved? Evidence suggests 
that U.S. IRBs rarely even try to communicate with RECs in host 
countries.
109
 Various commentators have observed that the welfare of 
human subjects involved in research would be better protected if U.S. 
IRBs worked more closely with RECs in countries where U.S.-sponsored 
research is conducted.
110
  
 
 
 107. U.S. Dept. of Health & Human Servs., Office for Human Research Prots., Federalwide 
Assurance Instructions, available at http://www.hhs.gov/ohrp/assurances/forms/fwainstructions.html. 
 108. OHRP identifies the following as acceptable research standards: 
 45 C.F.R. § 46; 
 21 C.F.R. § 50 and 21 C.F.R. § 56;  
 International Conference on Harmonization - Good Clinical Practice E6; 
 Council for International Organizations of Medical Sciences (CIOMS): International 
Ethical Guidelines for Biomedical Research Involving Human Subjects; 
 Canada Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans; 
 Indian Council of Medical Research: Ethical Guidelines for Biomedical Research on 
Human Participants  
See U.S. Dep’t. of Health and Human Servs., Office of Human Research Prots.’ International Research 
Standards, available at http://www.hhs.gov/ohrp/international/index.html (last visited Apr. 6, 2015); 
45 CFR § 46.101. 
 109. Macklin, supra note 2, at 717. 
 110. In a 2003 review of international clinical research, Daniel Fitzgerald, Angela Wasunna, and 
Jean Pape noted that  
IRBs from a wealthy sponsor country should ensure that a viable local ethics committee in the 
proposed host country will review the protocol. Further, IRBs in sponsoring countries should 
rely on the local ethics committee for obtaining important information about the host country. 
See Fitzgerald et al., supra note 105, at 14. The commentators further note that “the sponsor country 
IRB and the local IRB may possess complementary expertise and may be able to carry out a better 
review working together than either could working alone.” Id. 
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IV. ADDITIONAL CHANGES NEEDED 
Ethical research oversight in the U.S. has occurred via IRBs for more 
than thirty years accompanied by very few revelations of research abuse 
involving human subjects. Nonetheless, researchers and other critics have 
assessed the current IRB system as an inefficient, bureaucratic impediment 
to productive research that also fails to adequately protect human 
subjects.
111
 The ANPRM identified a number of potential reforms to 
federal regulations meant to improve IRB function but the suggested 
reforms did not go far enough. In fact, regulations by themselves cannot 
ensure that research is conducted according to ethical principles. It is, 
instead, the people applying the regulations who determine whether 
research is conducted according to ethical principles. This section 
evaluates the potential regulatory reforms and suggests additional tools 
that might be developed to aid IRBs in the process of providing ethical 
research oversight. 
A. Assessment of ANPRM Provisions 
1. Ensuring Risk-Based Protections 
The changes contemplated by the ANPRM to expand the category of 
research projects that qualify for expedited review would improve the 
calibration of the degree of risk that research poses to the degree of 
research oversight. Specifically, the contemplated changes would allow 
research that involves no more than minimal risk to forgo full IRB review, 
ultimately saving time and money without sacrificing human welfare. In 
addition, the change would likely improve researchers’ confidence in the 
ethics review system as researchers would be less likely to feel that their 
time and attention was being wasted on trying to justify trivial procedures. 
Particularly important to the contemplated change is the suggestion that 
the list of activities qualifying for expedited review would be routinely 
reassessed and updated, giving further credence to the notion that IRBs are 
reviewing studies for important ethical concerns rather than as simply a 
routine, bureaucratic manner.  
 
 
 111. Whitney & Schneider, supra note 28, at 398; Fost & Levine, supra note 40, at 2196; 
Hamburger, supra note 73, at 407. 
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2. Streamlining IRB Review of Multicenter Studies 
The ANPRM contemplates another important change to the Common 
Rule in suggesting that a single IRB be utilized for multicenter domestic 
studies. Mandating that institutions that participate in multicenter studies 
select a single IRB of record would prevent an unnecessary duplication of 
costs. As the ANPRM suggests, individual institutions could still choose 
to conduct their own internal ethics review but the duplication of time and 
expense would probably be so obvious that the mandated selection of an 
IRB of record would discourage this practice, saving tremendous 
resources overall. 
3. Improving Informed Consent  
By simply acknowledging the potential conflict, the ANPRM made a 
critical first step in reconciling the U.S. requirement for individual 
informed consent and the cultural practices in communities where research 
may be conducted but such concepts of individual consent are not 
supported. Adequately addressing needed reforms to the process of 
obtaining informed consent, however, requires acknowledging the ways in 
which proposed research is likely to be received by participants in the U.S. 
versus other countries. For example, in some developing countries, a 
substantial proportion of the population may be illiterate or semiliterate; 
requiring subjects to sign written consent documents in such communities 
would clearly undermine the notion that potential subjects were providing 
their true informed consent.
112
 In other communities, potential research 
subjects may be unfamiliar with medical research concepts that are 
referenced in consent documents. In its 2001 report on international 
research, the U.S. National Bioethics Advisory Commission (NBAC) 
contemplated this dilemma.
113
 NBAC emphasized that it was not sufficient 
to simply present information about the research to potential subjects but 
that researchers must ensure that potential subjects understood the 
information.
114
 Changes to the regulations requiring informed consent 
 
 
 112. NBAC International 2001, supra note 106, at 49. 
 113. Id. at 40–42. NBAC encouraged researchers to seek creative ways of presenting information 
that would be understood by potential research subjects, such as using analogies that are relevant to the 
local population. Id.  
 114. Id.; In its report, NBAC specifically recommended the following: 
Recommendation 3.4: Researchers should develop procedures to ensure that potential 
participants do, in fact, understand the information provided in the consent process and 
should describe those procedures in their research protocols. 
Washington University Open Scholarship
  
 
 
 
 
376 WASHINGTON UNIVERSITY GLOBAL STUDIES LAW REVIEW [VOL. 15:351 
 
 
 
 
from human research subjects needs to account for such necessary 
adaptions based on differences in populations where research is 
performed. In some cases, it may be necessary to document informed 
consent in ways that have not previously been considered, including, for 
example, by audio or video recording. It may also be necessary to 
eliminate the absolute requirement for documentation of informed consent 
under some circumstances and instead rely on the researcher’s protocols 
and testimony to ensure that informed consent is obtained from all 
research subjects.
115
 
4. Expanding Federal Regulations 
The expansion of federal regulations contemplated by the ANPRM 
would require IRB review for all research involving human subjects at 
research institutions that receive federal support. Unfortunately, this 
contemplated change does not go far enough. A further extension of 
federal ethics review oversight would require legislative action and should 
be the focus of future reform efforts in this area. After all, the level of 
interest in human welfare should not be dependent upon the source 
funding the relevant research.  
B. Establish Database of IRB Experience 
The suggested retrospective system of ethics review relies on the 
researcher to implement policies in the way that seems most appropriate to 
him or her. Since IRB members are frequently colleagues of the 
researchers whose studies they review, we would expect that IRB 
members already have this level of deference. However, the very fact that 
each consent form, promotional flier, and other documentation about a 
research study must be approved by the IRB undermines this sense of 
deference and directs the resources of both IRB members and researchers 
away from truly improving research studies and misdirects it to identifying 
inconsequential errors. Thus, a retrospective ethics review system would 
 
 
Recommendation 3.5: Researchers should consult with community representatives to develop 
innovative and effective means to communicate all necessary information in a manner that is 
understandable to potential participants. When community representatives will not be 
involved, the protocol presented to the ethics review committee should justify why such 
involvement is not possible or relevant.  
Id. at 42. 
 115. Circumstances that might warrant such treatment include research studies that qualify for 
expedited review conducted in communities that object to the use of recording devices. 
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be largely beneficial in that it would restore a sense of deference for the 
researcher while at the same time saving on administrative costs and IRB 
members’ time since only a fraction of research studies involving human 
subjects would be reviewed. 
One potential downside of adopting a retrospective review system is 
that it may lead to a shift away from research participation as Alex London 
suggests.
116
 More likely, however, there will only be a modest increase in 
public unease about biomedical research as a result of such change. In fact, 
public trust in the current review system may be misplaced since often 
IRBs are made up of researchers’ own colleagues where incentives to 
approve research studies are plentiful. Instead, I propose adapting the 
current prospective research oversight system to include analogous review. 
Currently there is no mechanism for an IRB to capitalize on the collective 
knowledge of other IRBs when reviewing a given research study. 
However, the current system might be adapted such that studies are 
randomly selected for follow-up audit-type review. Outcomes of research 
studies that are reviewed retrospectively would be compared with 
information from the IRB’s original discussion about the study and a 
database of such collective information could be established. Although the 
logistical efforts required to establish such a system would be immense, 
the long-term benefits would be more substantial. Even where an IRB was 
charged with reviewing a research protocol to which there was no 
comparable study in the database, there would likely still be some useful 
information in the database for review. For example, an entirely novel 
protocol might be targeted to a subject population that had been targeted 
by a previous study. IRB members could thus consider the review and 
assessment of both recruiting materials and consent documents from the 
original study when reviewing similar materials for the new protocol.  
C. IRBs as Facilitators 
As previously mentioned, studies analyzing the work of IRB panels 
have established that IRBs routinely fail to discuss some of the 
fundamental criteria for regulatory approval as they pertain to a given 
research study.
117
 Such criteria include risk minimization, risk/benefit 
comparison and data monitoring.
118
 Shifting the role of the IRB from 
reviewer to facilitator, as Spellecy and May suggest, will re-direct 
 
 
 116. London, supra note 81, at 939. 
 117. Lidz & Garverich, supra note 74, at 394. 
 118. Id. 
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members’ energy and attention from details of scientific protocols and 
informed consent documents to discussions about research and ethics. One 
way of implementing such a philosophical change might be to require the 
IRB chairperson to open each discussion of a study with a broad question 
along the lines of “What is it that the researcher seeks to study? What 
about such a study is ethical? What might be unethical?” The IRB would 
thus start their discussion of the proposed research study focusing not on 
the specifics of the study protocols but generally on the ultimate goal of 
the researcher.  
Another simple but effective tool to combat oversights in IRB 
discussions would be to provide each IRB with a standard agenda 
structured around the regulatory criteria for IRB approval. The agenda 
would aid IRB members as a visual reminder of what has and has not been 
discussed as they proceed through a particular review. In addition, 
establishing a routine for the review of each research proposal will make it 
less likely that any critical discussion is omitted. 
D. Improve IRB Representation 
Commentators on the federal oversight of human subjects research 
have routinely highlighted the lack of ethics education for both research 
investigators and IRB members as an important target for reform.
119
 An 
informal survey of academic and independent IRBs reveals that a number 
require research investigators to complete some type of ethics training 
prior to submitting materials for review. Ethics education requirements for 
IRB members, if any, are unclear. Importantly, the regulations of the 
Common Rule do not establish any ethics training requirements nor were 
any mentioned in the contemplated reforms outlined in the ANPRM. 
According to the regulations, however, IRBs are necessarily made up of a 
diverse group of people with different experience related to science, 
medicine, and philosophy. Requiring all IRB members to engage in 
ongoing ethics education programming will enable members to review and 
discuss research proposals with the same language in mind which is 
critical when considering new and complex ethical issues. Furthermore, a 
requirement for continuing ethics education will ensure that as knowledge 
about given procedures development and standards change, for instance, 
all IRB members have current information. In addition, changes to the 
Common Rule should adopt NBAC’s recommendation that at least 
 
 
 119. NBAC 2001, supra note 30; Bowen, supra note 96, at 557. 
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twenty-five percent of an IRB’s members be a combination of 
nonscientists and unaffiliated members.
120
 Such an increase in diversity 
will lessen the likelihood of conflict of interest problems, which 
undermine both the system of ethical oversight and biomedical research. 
Another tool for improving IRB representation is the potential for 
developing specialized central IRBs. Such IRBs would be made up of 
members with expertise in a particular type of biomedical study, the 
cultural norms of a given region/community, or simply with considerable 
experience in reviewing a certain type of research protocol that make them 
uniquely suited to review a given category of research proposals. The 
development and use of specialized IRBs would alleviate some of the 
burdens of overworked reviewers who often lack the time and 
administrative resources required to adequately familiarize themselves 
with uncommon research techniques or the cultural expectations of a 
community that is a proposed research site. 
CONCLUSION 
Although proposed reforms to current policies on research involving 
human subjects contemplate many potentially useful changes, they do not 
fully address the needs of an ever-evolving biomedical research world. 
Additional reforms that focus on establishing a means to share information 
between IRBs, the importance of discussions on ethics, and continuing 
education for IRB members are needed to improve the efficacy and 
efficiency of human research oversight.  
Andrea S. Nichols
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